

=> d his

(FILE 'HOME' ENTERED AT 15:09:53 ON 13 NOV 2007)

FILE 'REGISTRY' ENTERED AT 15:10:15 ON 13 NOV 2007

L1 STRUCTURE UPLOADED

L2 7 S L1


L3 169 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:11:42 ON 13 NOV 2007

L4 31 S L3

=> d que l4 stat

L1 STR



G1 O, S, N

G2 C, O, S, N

G3 Cb, [@1], [@2]

Structure attributes must be viewed using STN Express query preparation.

L3 169 SEA FILE=REGISTRY SSS FUL L1


L4 31 SEA FILE=CAPLUS ABB=ON PLU=ON L3

=> d l-31 ibib iabs hitstr

L4 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:1034875 CAPLUS
 DOCUMENT NUMBER: 147:439369
 TITLE: New therapies for immune thrombocytopenic purpura
 AUTHOR(S): Andemariam, Bires; Bussel, James
 CORPORATE SOURCE: New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
 SOURCE: Current Opinion in Hematology (2007), 14(5), 427-431
 CODEN: COHEP4; ISSN: 1065-6251
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: English
 ABSTRACT: A review. Clin. investigation of novel therapies in immune thrombocytopenic purpura is undergoing a revolution that has the potential to change the standard of care. While older therapies are experiencing a rebirth by being given a new spin, newer agents such as thrombopoietins are showing significant promise.

IT 496775-61-2, Eltrombopag
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (thrombopoietin receptor agonist eltrombopag could have clin. therapeutic potential against immune thrombocytopenic purpura)
 RN 496775-61-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(2Z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:627373 CAPLUS
 DOCUMENT NUMBER: 147:513671
 TITLE: Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist
 AUTHOR(S): Jenkins, Julian M.; Williams, Daphne; Deng, Yanli; Uhl, Joanne; Kitchen, Valerie; Collins, David; Erickson-Miller, Connie L.
 CORPORATE SOURCE: GlaxoSmithKline, Collegeville, PA, USA
 SOURCE: Blood (2007), 109(11), 4739-4741
 CODEN: BLOODW; ISSN: 0006-4971
 PUBLISHER: American Society of Hematology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ABSTRACT: Eltrombopag (SB-497115) is a first-in-class, oral, small-mol., nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a treatment for thrombocytopenia of various etiologies. In this phase I placebo-controlled clin. trial in 73 healthy male subjects, eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. The pharmacokinetics of eltrombopag were dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner. There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication. These observations indicate that eltrombopag is a once-daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging further studies in patients with thrombocytopenia.

IT 496775-61-2, Eltrombopag
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (study of eltrombopag, oral nonpeptide thrombopoietin receptor agonist)
 RN 496775-61-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(2Z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:866572 CAPLUS
 DOCUMENT NUMBER: 147:204037
 TITLE: Trends of clinical application of peptide and non-peptide compounds that bind c-Mpl
 AUTHOR(S): Kurata, Yoshiyuki
 CORPORATE SOURCE: Sch. of Medicine, Osaka Univ., Japan
 SOURCE: Medic Oncology (2007), 4(1), 64-72
 CODEN: WOENAJ; ISSN: 1349-2179
 PUBLISHER: Meiji Shoin
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: Japanese
 ABSTRACT: A review on trends of clin. application of peptide and non-peptide compds. that bind c-Mpl.


IT 496775-61-2, Eltrombopag
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (trends of clin. application of peptide and non-peptide compds. that bind c-Mpl)
 RN 496775-61-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(2Z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:593485 CAPLUS
 DOCUMENT NUMBER: 147:52801
 TITLE: Preparation of amide containing heterocyclic compounds as thrombopoietin activity modulators
 INVENTOR(S): Zhi, Lin; Phillips, Dean P.; Dalgard, Jackline E.; Penuliar, Richard J.; McNeill, Matthew H.; Chen, Jun-Hung; Cuervo, Catalina; Higuchi, Robert; Li, Yongkai; Long, Oliver; Van Overen, Cornelis Arjan
 PATENT ASSIGNEE(S): Ligand Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 271pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062078	A2	20070531	WO 2006-US45129	20061121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW				
RF: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM				
PRIORITY APPL. INFO.: US 2005-739339P P 20051123				
OTHER SOURCE(S): MARPAT 147:52801				
GRAPHIC IMAGE: US 2006-837653P P 20060814				



ABSTRACT:
 The title compds. such as I and II [R1 = H, halo, NO2, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, haloalkyl, etc.; R5 = H, halo, alkyl, etc.; R6 = alkyl, haloalkyl, heteroalkyl, etc.; R12 = H, halo, alkyl, etc.; R13 = H, halo, CN, etc.; a = 0-3; Q = monocyclic or bicyclic aromatic ring optionally containing one or more heteroatoms, and optionally fused with a non-aromatic heterocycle or carbocycle; U = O, C(O), (un)substituted NH, CH2, null; Y = 1-4 atom spacer comprising one or more groups selected from alkyl, heteroalkyl, Ph, heteroaryl], useful for treating thrombocytopenia and a condition affecting the nervous system, were prepared. Thus, treating 3'-[N'-[1-(3,5-dimethylphenyl)-2-oxo-6-trifluoromethyl-1,2-dihydroindol-3-ylidene]hydrazinyl]-2'-hydroxybiphenyl-3-carboxylic acid with triphosgene afforded 3'-[1-(3,5-dimethylphenyl)-2-oxo-


L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
6-trifluoromethyl-1,2-dihydroindol-3-ylideneamino]-2-oxo-2,3-dihydrobenzoxazol-7-yl]benzoic acid. The invention also relates to pharmaceutical compds. comprising the invention compds., methods of modulating the activity a thrombopoietin receptor using said compds., methods of identifying compds. as thrombopoietin receptor modulators, and methods of treating disease by administering the invention compds. to a patient in need thereof.

IT 939433-87-1P 939433-88-2P 939433-91-7P
939433-96-2P 939434-16-9P 939434-34-1P
939435-13-9P 939435-21-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic thrombopoietin activity modulating compds. for treating thrombocytopenia and a condition affecting the nervous system)

RN 939433-87-1 CAPLUS
CN Benzoic acid, 3-[4-[2-[3-(2,3-dihydro-1H-inden-2-yl)-2-hydroxyphenyl]hydrazinylidene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)




RN 939433-88-2 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-4-[2-[2-hydroxy-3-(1H-inden-2-yl)phenyl]hydrazinylidene]-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)




RN 939433-91-7 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-4-[2-(2-hydroxy-3',4'-dimethyl[1,1'-biphenyl]-3-yl)hydrazinylidene]-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)

L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 939433-96-2 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-4-[2-(2-hydroxy-3',5'-dimethyl[1,1'-biphenyl]-3-yl)hydrazinylidene]-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)




RN 939434-16-9 CAPLUS
CN Benzoic acid, 3-[4-[2-(5-chloro-3-cyclohexyl-2-hydroxyphenyl)hydrazinylidene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)


L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 939434-34-1 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-4-[2-(2-hydroxy-3',4',5-trimethyl[1,1'-biphenyl]-3-yl)hydrazinylidene]-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)




RN 939435-13-9 CAPLUS
CN Benzoic acid, 3-[4-[2-[3-(3,4-dihydro-2-naphthalenyl)-2-hydroxyphenyl]hydrazinylidene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)



RN 939435-21-9 CAPLUS
CN Benzoic acid, 3-[4-[2-[3-(7-fluoro-3,4-dihydro-2-naphthalenyl)-2-hydroxyphenyl]hydrazinylidene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]]- (CA INDEX NAME)

L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:435850 CAPLUS
 DOCUMENT NUMBER: 146:428547
 TITLE: Non-peptide thrombopoietin receptor agonist for the preservation of platelet efficacy during storage
 INVENTOR(S): Erickson-Miller, Connie Lynn
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 34pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007044982	A2	20070419	WO 2006-US40494	20061013
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, RW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPL. INFO.: US 2005-726249P P 20051013
 OTHER SOURCE(S): MARPAT 146:428547

ABSTRACT:
 This invention relates to method for the preservation of human platelet lifespan and/or efficacy during storage which comprises the addition of an effective amount of a non-peptide TPO receptor agonists to a storage solution containing human platelets.

IT 376591-84-3 376591-92-3 376592-02-8
 376592-38-0 376592-42-6 376592-47-1
 376592-56-2 376592-59-5 376592-61-9
 376592-63-1 376592-66-4 376592-70-0
 376592-76-6 376592-78-8 376592-79-9
 376592-83-5 376592-84-6 376592-85-7
 376592-87-9 376592-88-0 376592-92-6
 376592-94-8 376592-95-9 376592-96-0
 376592-97-1 376592-99-3 376593-00-9
 376593-02-1 376593-03-2 376593-05-4
 376593-08-7 376593-09-8 376593-10-1
 376593-12-3 376593-13-4 376593-14-5
 376593-15-6 376593-16-7 376593-17-8
 376593-19-0 376593-20-3 376593-23-6
 376593-24-7 376593-26-9 376593-27-0
 376593-31-6 376593-32-7 376593-33-8
 376593-34-9 376593-35-0 376593-37-2
 376593-39-4 376593-40-7 376593-42-9
 376593-47-4 376593-49-6 376593-50-9
 376593-53-2 376593-54-3 376593-56-5
 376593-57-6 376593-60-1 376593-61-2
 376593-62-3 376593-63-4 376593-64-5
 376593-65-6 376593-67-8 376593-68-9
 376593-70-3 376593-71-4 376593-73-6

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 376593-75-8 376593-77-0 376593-79-2
 376593-81-6 376593-84-9 376593-85-0
 376593-87-2 376593-89-4 376593-91-8
 376593-93-0 376593-95-2 376593-98-5
 376594-01-3 376594-03-5 376594-04-6
 376594-07-9 376594-12-6 376594-17-1
 376594-33-1 790693-70-8 790693-71-9
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (non-peptide thrombopoietin receptor agonist for preservation of platelet efficacy during storage)
 RN 376591-84-3 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-3'-hydroxy- (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

RN 376591-92-3 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-3'-hydroxy- (CA INDEX NAME)




L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-A




PAGE 2-A

RN 376592-02-8 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-(1,1-dimethylethyl)phenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-38-0 CAPLUS

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-(1,1-dimethylethyl)phenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-5-methyl- (CA INDEX NAME)




RN 376592-42-6 CAPLUS
 CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]diazinyl]-5-methyl- (CA INDEX NAME)




RN 376592-47-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-5'-fluoro-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-56-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 5'-chloro-3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-59-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-66-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-(5-chloro-2-hydroxy-4'-[2-(2-hydroxy-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- [1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376592-70-0 CAPLUS
CN [1,1'-Biphenyl]-3,5-dicarboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-61-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-(2-hydroxy-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- [1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376592-63-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-chloro-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methoxy-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376592-76-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-78-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methoxy-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-79-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-83-5 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)




RN 376592-84-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-88-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-1-(4-(methylamino)carbonyl)phenyl]-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-92-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-N-(methylsulfonyl)- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-85-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-87-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-94-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-95-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-1-(4-methylphenyl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-96-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-97-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-fluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-99-3 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethoxy)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-00-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3-ethoxy-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-02-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methylethoxy)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-03-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-(1,1-dimethylethyl)-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-05-4 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-(2,3,5,6-tetrafluoro-4-methylphenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-08-7 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-fluoro-3-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-09-8 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-phenyl-, 4-[2-[2-hydroxy-3'-(4-fluorophenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-10-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-phenyl-, 4-[2-[2-hydroxy-3'-(4-fluorophenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazole-4,5-dione, 1-(4-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)



RN 376593-16-7 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(4-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-17-8 CAPLUS
CN 1H-Pyrazole-4,5-dione, 3-methyl-1-[4-(trifluoromethyl)phenyl]-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-19-0 CAPLUS
CN 1H-Pyrazole-4,5-dione, 3-methyl-1-[4-(trifluoromethyl)phenyl]-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-12-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methoxy-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)



RN 376593-13-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methoxy-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-14-5 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-15-6 CAPLUS


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-20-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(4-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-23-6 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-24-7 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 dihydro-5-oxo-3-(2-pyridinyl)-4H-pyrazol-4-ylidenehydrazinyl]-2'-hydroxy-
 (CA INDEX NAME)




RN 376593-26-9 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3-fluoro-4-methylphenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)




RN 376593-27-0 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3-fluoro-4-methylphenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-33-8 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3-fluoro-4-methylphenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)




RN 376593-34-9 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3,4,5,6-tetrafluorophenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)




RN 376593-35-0 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3,4,5,6-tetrafluorophenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-31-6 CAPLUS
 CN Carbamic acid, N-[3'-(2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl)-2'-hydroxy[1,1'-biphenyl]-3-yl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 376593-32-7 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-37-2 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3,4-difluorophenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)




RN 376593-39-4 CAPLUS
 CN 1H-Pyrazolo-4,5-dione, 1-(3,4-dimethylphenyl)-3-(methoxymethyl)-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA
 INDEX NAME)




L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376593-40-7 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-difluorophenyl)-3-methyl-,
 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazine] (CA
 INDEX NAME)




RN 376593-42-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(trifluoromethyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-47-4 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-6-fluoro-2'-hydroxy- (CA INDEX NAME)




L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-53-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methyl-1H-pyrrol-3-yl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-54-3 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(1-methyl-1H-pyrrol-3-yl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazine] (CA INDEX NAME)




RN 376593-56-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3-(2-furanyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-49-6 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-propyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-50-9 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-propyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazine] (CA INDEX NAME)



L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-57-6 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-furanyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazine] (CA INDEX NAME)




RN 376593-60-1 CAPLUS
 CN Methanesulfonamide, N-[3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)



L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-61-2 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[3'-[2-[1-(3-fluoro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376593-62-3 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[3'-[2-[1-(4-fluoro-3-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-63-4 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-difluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)




RN 376593-64-5 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-(3'-amino-2-hydroxy[1,1'-biphenyl]-3-yl)hydrazone] (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-65-6 CAPLUS
CN Guanidine, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376593-67-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-68-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-ethyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-70-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-thienyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-71-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-cyclopropyl-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
hydroxy- (CA INDEX NAME)




RN 376593-73-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-thiazolyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-75-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-77-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methylethyl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-79-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-[(phenylmethoxy)methyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-81-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-ethyl-1,5-dihydro-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-84-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-85-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(hydroxymethyl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-87-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-5-oxo-3-[(phenylmethoxy)methyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-89-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(methylthio)methyl]-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-91-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-98-5 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376594-01-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,5-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-93-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-5-oxo-3-(3-thienyl)-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-95-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-(methylthio)methyl]-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-03-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-4'-hydroxy- (CA INDEX NAME)




RN 376594-04-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-chloro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-07-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-4'-hydroxy- (CA INDEX NAME)




RN 376594-12-6 CAPLUS
CN Phosphonic acid, P-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-17-1 CAPLUS
CN [1,1'-Biphenyl]-3,4-dicarboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376594-33-1 CAPLUS
CN [1,1'-Biphenyl]-3-sulfonic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790693-70-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(methoxymethyl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



RN 790693-71-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2',6-dihydroxy- (CA INDEX NAME)

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2007:194747 CAPLUS
 DOCUMENT NUMBER: 146:474542
 TITLE: Thrombopoietin receptor agonists: present and future
 AUTHOR(S): Michel, Marc
 CORPORATE SOURCE: Centre de reference sur les cytopénies auto-immunes, service de médecine interne, Hôpital Henri Mondor, Créteil, F-94010, Fr.
 SOURCE: Hematologie (2006), 12(5), 305-314
 CODEN: HEMAF2; ISSN: 1264-7527
 PUBLISHER: John Libbey Eurotext
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: French

ABSTRACT:
 A review. More than 10 years after the cloning of thrombopoietin (Tpo), platelet transfusions are still the only way to manage myeloablative chemotherapy-induced thrombocytopenias. The initial development of recombinant Tpo has been disappointing since its clin. efficacy was not demonstrated in the most critical situations and some cases of severe thrombocytopenias induced by neutralizing antibodies crossreacting with endogenous Tpo had been reported. More recently, some Tpo-receptor agonists or «Tpo mimetic agents» have been developed by pharmaceutical companies and two of them, AMG 531 and eltrombopag have entered into clin. phase II/III studies. Preliminary studies, mainly performed in patients with immune thrombocytopenic purpura (ITP), have shown a promising 80-85 % response rate with a relatively good short-term safety profile. Ongoing and future studies will be helpful to answer the following questions: (1) What could be the place of Tpo-R agonists in the treatment of ITP and (2) Will these mols. show a good efficacy/safety ratio for the management of the most critical situations in hematology, such as myelodysplasia-associated or chemotherapy-induced chronic thrombocytopenias.

IT 496775-61-2, Eltrombopag
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Thrombopoietin receptor agonists present and future)

RN 496775-61-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(2Z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:18643 CAPLUS
 DOCUMENT NUMBER: 146:329572
 TITLE: Eltrombopag
 AUTHOR(S): Revill, P.; Serradell, N.; Boles, J.
 CORPORATE SOURCE: Prous Science, Barcelona, 08060, Spain
 SOURCE: Drugs of the Future (2006), 31(9), 767-770
 CODEN: DRFLUD; ISSN: 0377-8282
 PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: English

ABSTRACT:
 A review. Eltrombopag is an orally available small-mol. platelet growth factor being developed for the treatment of thrombocytopenia, a condition in which a reduced number of platelets in the bloodstream predisposes the patient to bleeding. Thrombocytopenia complicates a number of diseases, including end-stage liver disease, chronic hepatitis C virus (HCV) infection, certain myelo-suppressive therapies (including intensive chemotherapies) and chronic immune thrombocytopenic purpura (ITP). Eltrombopag interacts with the thrombopoietin receptor of bone marrow megakaryocytes to stimulate the production of new platelets. In patients with ITP and patients with HCV-associated thrombocytopenia, eltrombopag significantly increased platelet counts compared to placebo.

IT 496775-61-2, Eltrombopag
 RL: ADV (Adverse effect, including toxicity); DNA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Pharmacol. of eltrombopag in relation to thrombocytopenia treatment)
 RN 496775-61-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(2Z)-1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

ACCESSION NUMBER: 2005:1314253 CAPLUS
 DOCUMENT NUMBER: 144:51572
 TITLE: Preparation of diazenyl pyrazoles as thrombopoietin activity modulators
 INVENTOR(S): Zhi, Lin; Kallel, E. Adam; Phillips, Dean P.
 PATENT ASSIGNEE(S): Ligand Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXAD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005/18551	A2	20051215	WO 2005-US18924	20050527
WO 2005/18551	A3	20060526		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, VU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KS, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2007/29539	A1	20070607	US 2006-562327	20061121
PRIORITY APPLN. INFO.:			US 2004-575196P	P 20040528
			WO 2005-US18924	A1 20050527
OTHER SOURCE(S):			CASREACT 144:51572; WARPAT 144:51572	
GRAPHIC IMAGE:				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

ABSTRACT:
 The title compds. I or II [R1 = CO2R10, CONR10R11, SO3R10, a carboxylic acid biosphere; R2, R3 = H, alkyl, haloalkyl, etc.; or R2 and R3 are independently absent or together form (un)substituted olefin or are linked to form (un)substituted ring or one of R2 or R3 is linked to R1 to form (un)substituted ring; R4 = H, F, Cl, Br, etc.; R5 = H, F, CO2H, etc.; R6 = H, alkyl, heteroalkyl, etc.; R7 = H, alkyl, haloalkyl, etc.; R10 = H, alkyl, haloalkyl, heteroalkyl; R11 = H, alkyl, haloalkyl, etc.; Z = a 2-5 atom spacer selected from (un)substituted aryl, heteroaryl, etc.; n = 0-1; with provisos], useful for the treatment of diseases and conditions associated with modulating a thrombopoietin activity (no data), were prepared and disclosed. The general procedures for synthesis of compds. I and II (such as III) are described.


IT 871361-26-IP 871361-27-2P 871361-28-3P
 871361-29-4P 871361-30-7P 871361-31-8P
 871361-32-9P 871361-34-1P 871361-35-2P
 871361-36-3P 871361-37-4P 871361-38-5P
 871361-39-6P 871361-40-9P 871361-41-0P
 871361-42-1P 871361-43-2P 871361-44-3P
 871361-45-4P 871361-46-5P 871361-48-7P
 871361-49-8P 871361-50-1P 871361-51-2P
 871361-52-3P 871361-54-5P 871361-55-6P
 871361-56-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Therapeutic use): BIOL (Biological study): PREP (Preparation): USES
(Uses)


RN 871361-26-1 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)




RN 871361-27-2 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 5'-chloro-3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)




RN 871361-28-3 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)




RN 871361-31-8 CAPLUS
CN [1,1'-Biphenyl]-4-ethanethioic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)




RN 871361-32-9 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-5'-fluoro-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)




L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(phenylmethyl)- (9C1) (CA INDEX NAME)




RN 871361-29-4 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]- α -ethyl-2'-hydroxy- (9C1) (CA INDEX NAME)




RN 871361-30-7 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)



L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-34-1 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α ,5'-dimethyl- (9C1) (CA INDEX NAME)




RN 871361-35-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α , α -dimethyl- (9C1) (CA INDEX NAME)



L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-36-3 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, α -butyl-3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)




RN 871361-37-4 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -(1-methylethyl)- (9C1) (CA INDEX NAME)

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-40-9 CAPLUS
CN Acetic acid, [3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-4-yl]oxy- (9C1) (CA INDEX NAME)




RN 871361-41-0 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-5'-fluoro-2'-hydroxy- α -methyl- (9C1) (CA INDEX NAME)

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 871361-38-5 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl-, (aS)- (9C1) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 871361-39-6 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- α -methyl-, (eR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-42-1 CAPLUS
CN Glycine, N-[2-[3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-4-yl]-1-oxopropyl]-N-methyl- (9C1) (CA INDEX NAME)




RN 871361-43-2 CAPLUS
CN Glycine, N-[2-[3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-4-yl]-1-oxopropyl]-N-methyl-, ethyl ester (9C1) (CA INDEX NAME)


L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 871361-44-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-[(3,4-dimethylphenyl)-3-methyl-4-[[5-chloro-2-hydroxy-4'-[1-[(1H-tetrazol-5-yl)ethyl]](1,1'-biphenyl)]-3-yl]hydrazono] (9C1) (CA INDEX NAME)




RN 871361-45-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-[(3,4-dimethylphenyl)-3-methyl-4-[[2-hydroxy-4'-[1-[(1H-tetrazol-5-yl)ethyl]](1,1'-biphenyl)]-3-yl]hydrazono] (9C1) (CA INDEX NAME)




RN 871361-46-5 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1,5-dihydro-3-methyl-5-oxo-1-(4-propylphenyl)-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-α-methyl- (9C1) (CA INDEX NAME)

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-48-7 CAPLUS
CN Propanoic acid, 2-[[3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-5-methyl(1,1'-biphenyl)]-3-yl]oxy]-2-methyl- (9C1) (CA INDEX NAME)




RN 871361-49-8 CAPLUS
CN Glycine, N-[[3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy(1,1'-biphenyl)]-3-yl]carbonyl]- (9C1) (CA INDEX NAME)

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-50-1 CAPLUS
CN Glycine, N-[[3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy(1,1'-biphenyl)]-3-yl]carbonyl]-, ethyl ester (9C1) (CA INDEX NAME)




RN 871361-51-2 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-α-methoxy-5-methyl- (9C1) (CA INDEX NAME)

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 871361-52-3 CAPLUS
CN Butanoic acid, 2-[[5'-chloro-3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy(1,1'-biphenyl)]-3-yl]oxy]- (9C1) (CA INDEX NAME)




RN 871361-54-5 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-α-ethyl-2'-hydroxy- (9C1) (CA INDEX NAME)

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 871361-55-6 CAPLUS
CN Propanoic acid, 2-[[[3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-4-yl]oxy]- (9C1) (CA INDEX NAME)




RN 871361-56-7 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 3'-[[[1-(3,5-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-4,4'-dimethyl- (9C1) (CA INDEX NAME)

L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:405369 CAPLUS
DOCUMENT NUMBER: 142:463730
TITLE: Preparation of 2-(3,4-dimethylphenyl)-4-[[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt
INVENTOR(S): Brook, Christopher S.; Ping, Li-Jen J.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041867	A2	20050512	WO 2004-US34944	20041021
WO 2005041867	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285462	A1	20050512	AU 2004-285462	20041021
CA 2543216	A1	20050512	CA 2004-2543216	20041021
EP 1684748	A2	20060802	EP 2004-796011	20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015704	A	20061219	BR 2004-15704	20041021
CN 1897937	A	20070117	CN 2004-80038488	20041021
JP 2007509159	T	20070412	JP 2006-536801	20041021
IN 2006D02031	A	20070622	IN 2006-DN2031	20060413
US 2007072922	A1	20070329	US 2006-576411	20060420
MX 2006P040483	A	20060620	MX 2006-P44483	20060421
NO 2006002111	A	20060718	NO 2006-2111	20060511
PRIORITY APPL. INFO.:			US 2003-513481P	P 20031022
OTHER SOURCE(S):		CASREACT 142:463730	WO 2004-US34944	W 20041021
GRAPHIC IMAGE:				



ABSTRACT:

An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-[[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dihydropyrazol-3-one (1), is prep. by treating 2-(3,4-dimethylphenyl)-4-[[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one with choline hydroxide. The comp. 1 is useful as an agonist of thrombopoietin receptor in enhancing platelet prodn., particularly in the treatment of thrombocytopenia. A tablet and injectable parenteral compn. contg. 1 are described.

IT 851606-62-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(3,4-dimethylphenyl)-4-[[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt as thrombopoietin receptor agonist)
RN 851606-62-7 CAPLUS
CN Ethanaminium, 2-hydroxy-N,N-trimethyl-, salt with 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[[[2-hydroxy-3'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]azo]-5-methyl-3H-pyrazol-3-one (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 851606-61-6
CMF C25 H21 N8 O2




CM 2

CRN 62-49-7
CMF C5 H14 N O

Me₃N-CH₂-CH₂-OH

IT 376592-42-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-(3,4-dimethylphenyl)-4-[[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt as thrombopoietin receptor agonist)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)

L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:965013 CAPLUS
 DOCUMENT NUMBER: 141:406144
 TITLE: Methods for treating degenerative diseases/injuries using nonpeptide thrombopoietin receptor agonists
 INVENTOR(S): Erickson-Miller, Connie L.; Jenkins, Julian
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODE: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096154	A2	20041111	WO 2004-US13468	20040429
WO 2004096154	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1622609	A2	20060208	EP 2004-760459	20040429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, JP			
JP 2006525352	T	20061109	JP 2006-514185	20040429
US 2007105824	A1	20070510	US 2006-554811	20061110
PRIORITY APPL. INFO.:			US 2003-466540P	P 20030429
			US 2003-471554P	P 20030519
			US 2003-495034P	P 20030814
			US 2004-54977P	P 20040304
			US 2004-554581P	P 20040319
			US 2004-556390P	P 20040325
			WO 2004-US13468	W 20040429

OTHER SOURCE(S): MARPAT 141:406144
 ABSTRACT:
 Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal. An injectable form for administering the present invention is produced by stirring 1.5 % by weight of 4'-[N-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazinyl]-3'-hydroxy biphenyl-3-carboxylic acid in 10 % by volume propylene glycol in water.

IT 376591-84-3 376591-92-3 376592-02-8
 376592-38-0 376592-42-6 376592-47-1
 376592-56-2 376592-58-5 376592-61-9
 376592-63-1 376592-66-4 376592-70-0
 376592-76-6 376592-78-8 376592-79-9
 376592-83-5 376592-84-6 376592-85-7
 376592-87-9 376592-88-0 376592-92-6
 376592-94-8 376592-95-9 376592-96-0
 376592-97-1 376592-99-3 376593-00-9
 376593-02-1 376593-03-2 376593-05-4

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

376593-08-7 376593-09-8 376593-10-1
 376593-12-3 376593-13-4 376593-14-5
 376593-15-6 376593-16-7 376593-17-8
 376593-19-0 376593-20-3 376593-23-6
 376593-24-7 376593-26-9 376593-27-0
 376593-31-6 376593-32-7 376593-33-8
 376593-34-9 376593-35-0 376593-37-2
 376593-39-4 376593-40-7 376593-42-9 37659
 3-47-4 376593-49-6 376593-50-9
 376593-53-2 376593-54-3 376593-56-5
 376593-57-6 376593-60-1 376593-61-2
 376593-62-3 376593-63-4 376593-64-5
 376593-65-6 376593-67-8 376593-68-9
 376593-70-3 376593-71-4 376593-73-6
 376593-75-8 376593-77-0 376593-79-2
 376593-81-6 376593-84-9 376593-85-0
 376593-87-2 376593-89-4 376593-91-8
 376593-93-0 376593-95-2 376593-98-5
 376594-01-3 376594-03-5 376594-04-6
 376594-07-9 376594-12-6 376594-17-1
 376594-33-1 790693-70-8 790693-71-9
 RL: RSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as nonpeptide TPO receptor agonist; nonpeptide thrombopoietin receptor
 agonists for treatment of degenerative diseases/injuries)
 RN 376591-84-3 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-3'-hydroxy- (CA INDEX NAME)



PAGE 1-A


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 376591-92-3 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-3'-hydroxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 376592-02-8 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-38-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-5-methyl- (CA INDEX NAME)




RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]diazinyl]-5-methyl- (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-59-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3,5-dioxo-4-pyrazolidinylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-61-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-4-[2-[2-hydroxy-4'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-47-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-5'-fluoro-2'-hydroxy- (CA INDEX NAME)




RN 376592-56-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 5'-chloro-3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376592-63-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-chloro-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-66-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-4-[2-[5-chloro-2-hydroxy-4'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376592-70-0 CAPLUS
CN [1,1'-Biphenyl]-3,5-dicarboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-76-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-78-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methoxy-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-79-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-methoxyphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-83-5 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-84-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-85-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-(trifluoromethyl)phenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-87-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-(trifluoromethyl)phenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-88-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-(trifluoromethyl)phenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-92-6 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-N-(methylsulfonyl)- (CA INDEX NAME)




RN 376592-94-8 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-97-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-fluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-99-3 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-1-(trifluoromethoxy)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-95-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-96-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-chlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-00-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-02-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-03-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-(1,1-dimethylethyl)-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-05-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-(2,3,5,6-tetrafluoro-4-methylphenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-10-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-phenyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-12-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methoxy-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-13-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-ethoxy-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-08-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-fluoro-3-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-09-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-phenyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-14-5 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 376593-15-6 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(4-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-16-7 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(4-fluoro-3-methylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-17-8 CAPLUS
CN 1H-Pyrazole-4,5-dione, 3-methyl-1-[4-(trifluoromethyl)phenyl]-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-19-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(4-pyridinyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-20-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(4-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-23-6 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-31-6 CAPLUS
CN Carbamic acid, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy(1,1'-biphenyl)-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 376593-32-7 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-24-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-pyridinyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-26-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3-fluoro-4-methylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-27-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-fluoro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376593-33-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-fluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-34-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 3-methyl-1-(2,3,4,5,6-pentafluorophenyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-35-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-(2,3,4,5,6-pentafluorophenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-37-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-difluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-39-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(methoxymethyl)-, 4-[2-[2-hydroxy-3-(trifluoromethyl)-2H-tetrazol-5-yl]]-1,1'-biphenyl-3-yl]hydrazone (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-49-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-propyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-50-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-propyl-, 4-[2-[2-hydroxy-3-(2H-tetrazol-5-yl)]-1,1'-biphenyl-3-yl]hydrazone (CA INDEX NAME)




L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-40-7 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-difluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3-(2H-tetrazol-5-yl)]-1,1'-biphenyl-3-yl]hydrazone (CA INDEX NAME)




RN 376593-42-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(trifluoromethyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-47-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-6-fluoro-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376593-53-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methyl-1H-pyrrol-3-yl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-54-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(1-methyl-1H-pyrrol-3-yl)-, 4-[2-[2-hydroxy-3-(2H-tetrazol-5-yl)]-1,1'-biphenyl-3-yl]hydrazone (CA INDEX NAME)




RN 376593-56-5 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3-(2-furanyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-57-6 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-furanyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)




RN 376593-60-1 CAPLUS
CN Methanesulfonamide, N-[3'-(2-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-61-2 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[3'-(2-[1-(3-fluoro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376593-62-3 CAPLUS
CN Methanesulfonamide, 1,1,1-trifluoro-N-[3'-(2-[1-(4-fluoro-3-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-63-4 CAPLUS
CN Methanesulfonamide, N-[3'-(2-[1-(3,4-difluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)




RN 376593-64-5 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-(3'-amino-2-hydroxy[1,1'-biphenyl]-3-yl)hydrazone] (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-65-6 CAPLUS
CN Guanidine, N-[3'-(2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376593-67-8 CAPLUS
CN 1H-pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-ethyl-, 4-[2-(3'-amino-2-hydroxy[1,1'-biphenyl]-3-yl)hydrazone] (CA INDEX NAME)


L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-68-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-((3,4-dimethylphenyl)-3-ethyl-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazinyl)-2'-hydroxy- (CA INDEX NAME)




RN 376593-70-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-thienyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-77-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methylethyl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-79-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-[(phenylmethoxy)methyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376593-71-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-cyclopropyl-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-73-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-thiazolyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-75-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-81-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-ethyl-1,5-dihydro-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-84-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-85-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(hydroxymethyl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-87-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-5-oxo-3-(phenylmethoxymethyl)-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-93-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-5-oxo-3-(3-thienyl)-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-95-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-(methythio)methyl]-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-89-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(methylthio)methyl]-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-91-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(3-thienyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-98-5 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376594-01-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,5-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-03-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-4'-hydroxy- (CA INDEX NAME)




RN 376594-04-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-chloro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-17-1 CAPLUS
CN [1,1'-Biphenyl]-3,4-dicarboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376594-33-1 CAPLUS
CN [1,1'-Biphenyl]-3-sulfonic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-07-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-4'-hydroxy- (CA INDEX NAME)




RN 376594-12-6 CAPLUS
CN Phosphonic acid, P-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 790693-70-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methoxymethyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



RN 790693-71-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2',6-dihydroxy- (CA INDEX NAME)

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:991360 CAPLUS
 DOCUMENT NUMBER: 140:42170
 TITLE: Preparation of arylazopyrazoles as thrombopoietin mimetics
 INVENTOR(S): Heerding, Dirk A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103686	A1	20031218	WO 2003-US17837	20030606
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, SN, TD, TG, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248630	A1	20031222	AU 2003-248630	20030606
EP 1556059	A1	20050727	EP 2003-757372	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, NM, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501164	T	20060112	JP 2004-510805	20030606
US 2005234020	A1	20051020	US 2004-516988	20041206
PRIORITY APPL. INFO.:			US 2002-386694P	P 20020606
			US 2003-463241P	P 20030416
			WO 2003-US17837	W 20030606

OTHER SOURCE(S): MARPAT 140:42170

GRAPHIC IMAGE:



ABSTRACT:

Title compds. I [R-R3 = H, (un)substituted alkyl, alkenyl, aryl, OH, SH, S(O)H, SO2H, NH2, CONH2, SO2NH2, CO2H, CHD, NO2, CN, halogen, cycloalkyl, P(O)(OH)2, SO3H, P(O)(OH)(OH), heterocyclylidenemethyl: m = 0-6; R4 = (un)substituted alkyl, aryl, OH, halogen; R5 = (un)substituted cycloalkyl] were prepared for use as thrombopoietin mimetics in treating thrombocytopenia (no data). Thus, cyclohexylhydrazine hydrochloride was treated with MeCOCH2CO2Me to give

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

2-cyclohexyl-5-methyl-2,4-dihydropyrazol-3-one which was treated with 3,2-H2N(HO)C6H3C6H4CO2H-2 to give I [R = 2-Ho2CC6H4, R1-R3 = H, R4 = Me, R5 = cyclohexyl, m = 0].

IT 634585-91-4P 634585-92-5P 634585-93-6P

634585-94-7P 634585-95-8P 634586-09-7P

634586-10-OP 634586-11-1P 634586-12-2P

634586-13-3P 634586-14-4P 634586-15-5P

634586-16-6P 634902-48-OP

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological)

study); PREP (Preparation); USES (Uses)

(preparation of arylazopyrazoles as thrombopoietin mimetics)

RN 634585-91-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(1-cyclohexyl-1,5-dihydro-3-methyl-

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)


5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-2'-hydroxy- (9C1) (CA INDEX NAME)

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 634585-94-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[[1-(3-ethylcyclopentyl)-1,5-dihydro-3-methyl-5-oxo-

4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]-2-methyl-, (2E)- (9C1)

(CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 634585-95-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[[1-(3-(1,1-dimethylpropyl)cyclopentyl)-1,5-dihydro-

3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]-2-methyl-,

(2E)- (9C1) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 634586-09-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(1-cyclohexyl-4,5-dihydro-3-methyl-

5-oxo-1H-pyrazol-4-yl)azo]-2'-hydroxy- (9C1) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



RN 634585-93-6 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[1-(trans-4-(1,1-dimethylethyl)cyclohexyl)-1,5-

dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-

hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)


5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)


5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

5-oxo-4H-pyrazol-4-ylidene)hydrazino]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 634586-10-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[1-[(4-(1,1-dimethylethyl)cyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-2'-hydroxy- (9C1) (CA INDEX NAME)




RN 634586-11-1 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[1-[(3,4-dimethylcyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-2'-hydroxy- (9C1) (CA INDEX NAME)


L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 634586-14-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[1-[(4-(1,1-dimethylethyl)cyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)




RN 634586-15-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[1-[(3,4-dimethylcyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 634586-12-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[1-[(3,4-dichlorocyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-2'-hydroxy- (9C1) (CA INDEX NAME)



RN 634586-13-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[1-[(3,4-dichlorocyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)


L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 634586-16-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[[1-[(3,4-dichlorocyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-3-hydroxyphenyl]methylene]- (9C1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 634902-48-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[1-[(4-(1,1-dimethylethyl)cyclohexyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-3-hydroxyphenyl]-2-methyl-, (2E)- (9C1) (CA INDEX NAME)

Double bond geometry as described by E or Z.

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:950750 CAPLUS
 DOCUMENT NUMBER: 140:5045
 TITLE: Preparation of (pyrazolidenehydrazino)[1,1'-biphenyl]-3-carboxylates as TPO receptor agonists for enhancing platelet production
 INVENTOR(S): Moore, Stephen
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003098992	A2	20031204	WO 2003-US16255	20030521
WO 2003098992	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AN, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2486697	A1	20031204	CA 2003-2486697	20030521
AU 2003241587	A1	20031212	AU 2003-241587	20030521
AU 2003241587	B2	20071004		
BR 2003010094	A	20050215	BR 2003-10094	20030521
EP 1534390	A2	20050601	EP 2003-731335	20030521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1652842	A	20050810	CN 2003-811370	20030521
JP 200526143	T	20050902	JP 2004-506532	20030521
RU 2284994	C2	20061010	RU 2004-137491	20030521
NZ 536272	A	20070831	NZ 2003-536272	20030521
ZA 2004008701	A	20060222	ZA 2004-8701	20041027
IN 2004DN03400	A	20070420	IN 2004-DN3400	20041102
MX 2004PA11522	A	20050214	MX 2004-PA11522	20041119
NO 2004005561	A	20041220	NO 2004-5561	20041220
US 2006178518	A1	20060810	US 2006-515304	20060222
PRIORITY APPL. INFO.:			US 2002-382871P	P 20020522
GRAPHIC IMAGE:			WO 2003-US16255	W 20030521

L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




ABSTRACT:
 The title bis(ethanolamine) salt (I), an improved thrombopoietin mimetic with enhanced solubility and bioavailability over the free base, was prepared from the free base and monoethanolamine in an appropriate solvent such as THF. Pharmaceutical tablet and injectable parenteral comps. are given, and pharmaceutical comps. comprising another therapeutically effective agent are claimed.

IT 496775-62-3P
 RL: PAC (Pharmacological activity): PRP (Properties): SPN (Synthetic preparation): THU (Therapeutic use): BIOL (Biological study): PREP (Preparation): USES (Uses)
 (preparation of (pyrazolidenehydrazino)biphenylcarboxylate salts as TPO receptor agonists for enhancing platelet production)
 RN 496775-62-3 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2(2)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-, compd. with 2-aminoethanol (1:2) (9C1) (CA INDEX NAME)

CM 1

CRN 496775-61-2
 CNF C25 H22 N4 O4

Double bond geometry as shown.



L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CM 2

CRN 141-43-5
 CNF C2 H7 N O

H2N-CH2-CH2-OH

IT 496775-61-2
 RL: PRP (Properties): RCT (Reactant): RACT (Reactant or reagent) (preparation of (pyrazolidenehydrazino)biphenylcarboxylate salts as TPO receptor agonists for enhancing platelet production)
 RN 496775-61-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2(2)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- (CA INDEX NAME)


Double bond geometry as shown.



L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 2002:55523 CAPLUS
 DOCUMENT NUMBER: 137:119693
 TITLE: Regulated activation of cell-membrane receptors by metal-chelating agonists
 INVENTOR(S): Delorme, Evelyn O.; Duffy, Kevin J.; Lamb, Peter I.; Luengo, Juan I.; Tian, Shin-Shay C.
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA; Ligand Pharmaceuticals
 SOURCE: PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057300	A1	20020725	WO 2001-US50777	20011219
W:	AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, CN, CO, GW, ML, MR, NE, SN, TD, TG			
CA 2432800	A1	20020725	CA 2001-2432800	20011219
AU 2002241734	A1	20020730	AU 2002-241734	20011219
EP 1351979	A1	20031015	EP 2001-988426	20011219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004532614	T	20041028	JP 2002-557976	20011219
US 2004053299	A1	20040318	US 2003-451296	20030619
PRIORITY APPLN. INFO.:			US 2000-257002P	P 20001221
			WO 2001-US50777	W 20011219

GRAPHIC IMAGE:




ABSTRACT:

The invention deals with methods for activating dimeric or oligomeric cell surface receptors which comprises mutating either one specific amino acid within the transmembrane domain of the receptor to histidine or mutating 2 ap. amino acids, preferably 3 residues apart, within the transmembrane domain to


L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 threonine and histidine and thereafter contacting the mutated cell surface receptor with a metal-chelating receptor agonist such as those represented by 1 (R = H or alkyl; Ar = substituted aryl). Transfection of these modified receptors into host cells provides numerous therapeutic opportunities in gene therapy and other applications related to inducible signal transduction in transduced cells. Examples are provided showing that histidine at amino acid position 499 in the human thrombopoietin receptor (transmembrane domain) is required for 1 activity, and that mutation of murine GCSF-R transmembrane domain Cys610 to His resulting in the mutant becoming responsive to 1 and further mutation of Gly607 to His resulted in higher level of sensitivity than the single mutation. Examples are 1 synthesis are also provided.

IT 443130-00-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (regulated activation of cell-membrane receptors by metal-chelating naphthalenylpyrazole agonists)
 RN 443130-00-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-, monohydrate (9C1) (CA INDEX NAME)



IT 376591-99-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (regulated activation of cell-membrane receptors by metal-chelating naphthalenylpyrazole agonists)
 RN 376591-99-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-, (9C1) (CA INDEX NAME)

L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT:


4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:56162 CAPLUS
 DOCUMENT NUMBER: 136:5987
 TITLE: Thrombopoietin mimetics
 INVENTOR(S): Duffy, Kevin J.; Erickson-Miller, Connie L.; Eppley, Daniel F.; Jenkins, Julian; Luengo, Juan I.; Liu, Nannan; Price, Alan T.; Shaw, Antony N.; Visonneau, Sophie; Wiggall, Kenneth
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA; Glaxo Group Limited
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089457	A2	20011129	WO 2001-US16863	20010524
WO 2001089457	A3	20020307		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, CN, CO, GW, ML, MR, NE, SN, TD, TG			
CA 2411468	A1	20011129	CA 2001-2411468	20010524
AU 200174938	A	20011203	AU 2001-74938	20010524
EP 1294378	A2	20030326	EP 2001-941599	20010524
EP 1294378	B1	20071003		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001011116	A	20030408	BR 2001-11116	20010524
HU 2003002257	A2	20031028	HU 2003-2257	20010524
HU 2003002257	A3	20070328		
JP 2003534257	T	20031118	JP 2001-585703	20010524
JP 3813875	B2	20060823		
NZ 522474	A	20041029	NZ 2001-522474	20010524
NZ 533308	A	20051028	NZ 2001-533308	20010524
AT 374772	T	20071015	AT 2001-941599	20010524
NO 2002005566	A	20030122	NO 2002-5566	20021120
IN 2002MNO1666	A	20041211	IN 2002-MNO1666	20021121
ZA 2002009561	A	20031020	ZA 2002-0561	20021125
MX 2002PA11621	A	20040517	MX 2002-PA11621	20021125
US 2004019190	A1	20040129	US 2003-296688	20030703
US 7160870	B2	20070109		
JP 2006137764	A	20060601	JP 2005-353686	20051207
US 2007179192	A1	20070802	US 2006-558071	20061109
US 2007129338	A1	20070607	US 2007-620260	20070105
PRIORITY APPLN. INFO.:			US 2000-207084P	P 20000525
			US 2000-228929P	P 20000830
			JP 2001-585703	A3 20010524
			WO 2001-US16863	W 20010524
			US 2003-296688	A1 20030703

OTHER SOURCE(S): MARPAT 136:5987
 GRAPHIC IMAGE:

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



ABSTRACT:

Pyrazolylidenehydrazino compds. such as 1 were prepared as thrombopoietin mimetics. Thus, 1 was prepared in 5 steps, the last of which involved reaction of 4-amino-3'-hydroxy-3-biphenylcarboxylic acid hydrochloride with 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one.


IT 376593-64-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(pyrazolylidenehydrazino)phenol derivs. as thrombopoietin mimetics)

RN 376593-64-5 CAPLUS

CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-4-[2-(3'-amino-2-hydroxy[1,1'-biphenyl]-3-yl)hydrazono] (CA INDEX NAME)



IT 376592-56-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(pyrazolylidenehydrazino)phenol derivs. as thrombopoietin mimetics)

RN 376592-56-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 5'-chloro-3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 376591-84-3P 376591-92-3P 376591-99-0P

376592-02-8P 376592-38-0P 376592-42-6P

376592-47-1P 376592-59-5P 376592-61-9P

376592-63-1P 376592-66-4P 376592-70-0P

376592-76-6P 376592-78-8P 376592-79-9P

376592-83-5P 376592-84-6P 376592-85-7P

376592-87-9P 376592-88-0P 376592-92-6P

376592-94-8P 376592-95-9P 376592-96-0P

376592-97-1P 376592-99-3P 376593-00-9P

376593-02-1P 376593-03-2P 376593-05-4P

376593-08-7P 376593-09-8P 376593-10-1P

376593-12-3P 376593-13-4P 376593-14-5P

376593-15-6P 376593-16-7P 376593-17-8P

376593-19-0P 376593-20-3P 376593-23-6P

376593-24-7P 376593-26-9P 376593-27-0P

376593-31-6P 376593-32-7P 376593-33-8P

376593-34-9P 376593-35-0P 376593-37-2P

376593-39-4P 376593-40-7P 376593-42-9P

376593-47-4P 376593-49-6P 376593-50-9P

376593-53-2P 376593-54-3P 376593-56-5P

376593-57-6P 376593-60-1P 376593-61-2P

376593-62-3P 376593-63-4P 376593-65-6P

376593-67-8P 376593-68-9P 376593-70-3P

376593-71-4P 376593-73-6P 376593-75-8P

376593-77-0P 376593-79-2P 376593-81-6P

376593-84-0P 376593-85-0P 376593-87-2P

376593-89-4P 376593-91-8P 376593-93-0P

376593-95-2P 376593-98-5P 376594-01-3P

376594-03-5P 376594-04-6P 376594-07-9P

376594-12-6P 376594-17-1P 376594-23-9P

376594-33-1P 376594-38-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)


(pyrazolylidenehydrazino)phenol derivs. as thrombopoietin mimetics)

RN 376591-84-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-3'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 376591-92-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-3'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 376591-99-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- (9CI) (CA INDEX NAME)




RN 376592-02-8 CAPLUS

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-38-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-[4-(1,1-dimethylethyl)phenyl]-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-5'-methyl- (CA INDEX NAME)




RN 376592-42-6 CAPLUS
 CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]diazinyl]-5-methyl- (CA INDEX NAME)


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-61-9 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-4'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)




RN 376592-63-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-chloro-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-47-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-5'-fluoro-2'-hydroxy- (CA INDEX NAME)




RN 376592-59-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3,5-dioxo-4-pyrazolidinylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376592-66-4 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[5-chloro-2-hydroxy-4'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)




RN 376592-70-0 CAPLUS
 CN [1,1'-Biphenyl]-3,5-dicarboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-76-6 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-78-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methoxy-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-79-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-methoxyphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-85-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376592-87-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376592-83-5 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)




RN 376592-84-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dichlorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)







RN 376592-88-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-1-[4-(methylamino)carbonyl]phenyl]-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)







RN 376592-92-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-N-(methylsulfonyl)- (CA INDEX NAME)


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




14 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-05-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-(2,3,5,6-tetrafluoro-4-methylphenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-08-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(4-fluoro-3-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-12-3 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methoxy-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 376593-13-4 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methoxy-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-14-5 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(1-methylethoxy)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-15-6 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(4-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-09-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-phenyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-10-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-phenyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-16-7 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(4-fluoro-3-methylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 376593-17-8 CAPLUS
CN 1H-Pyrazole-4,5-dione, 3-methyl-1-[4-(trifluoromethyl)phenyl]-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)




RN 376593-19-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(4-pyridinyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-20-3 CAPLUS

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(4-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone (CA INDEX NAME)



RN 376593-23-6 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-pyridinyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone (CA INDEX NAME)




RN 376593-24-7 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-pyridinyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 376593-31-6 CAPLUS
 CN Carbamic acid, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 376593-32-7 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3-fluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone (CA INDEX NAME)




RN 376593-33-8 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-fluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-26-9 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3-fluoro-4-methylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone (CA INDEX NAME)




RN 376593-27-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-fluoro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-34-9 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 3-methyl-1-(2,3,4,5,6-pentafluorophenyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)](1,1'-biphenyl)-3-yl]hydrazone (CA INDEX NAME)




RN 376593-35-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-(2,3,4,5,6-pentafluorophenyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-37-2 CAPLUS


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-difluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



RN 376593-39-4 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(methoxymethyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)




RN 376593-40-7 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-difluorophenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)




RN 376593-42-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 dihydro-5-oxo-3-(trifluoromethyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-47-4 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-6-fluoro-2'-hydroxy- (CA INDEX NAME)




RN 376593-49-6 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-propyl-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376593-50-9 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-propyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)




RN 376593-53-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methyl-1H-pyrrol-3-yl)-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-54-3 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(1-methyl-1H-pyrrol-3-yl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (CA INDEX NAME)



RN 376593-56-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3-(2-furanyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-57-6 CAPLUS
 CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-(2-furanyl)-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)][1,1'-biphenyl]-3-yl]hydrazone (CA INDEX NAME)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 376593-60-1 CAPLUS

CN Methanesulfonamide, N-[3'-[2-[1,5-dihydro-3-methyl-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)




RN 376593-61-2 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[3'-[2-[1-(3-fluoro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 376593-62-3 CAPLUS


CN Methanesulfonamide, 1,1,1-trifluoro-N-[3'-[2-[1-(4-fluoro-3-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 376593-67-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-3-ethyl-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-68-9 CAPLUS

CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-ethyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]]hydrazone (CA INDEX NAME)




L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-63-4 CAPLUS

CN Methanesulfonamide, N-[3'-[2-[1-(3,4-difluorophenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]-1,1,1-trifluoro- (CA INDEX NAME)



RN 376593-65-6 CAPLUS


CN Guanidine, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 376593-70-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-thienyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



RN 376593-71-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[3-cyclopropyl-1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-73-6 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(2-thiazolyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-75-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-77-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1-(3,4-dimethylphenyl)-1,5-dihydro-3-(1-methylethyl)-5-oxo-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-84-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1,5-dihydro-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-85-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1-(3,4-dimethylphenyl)-1,5-dihydro-3-(hydroxymethyl)-5-oxo-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-79-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-[(phenylmethoxy)methyl]-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-81-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(3-ethyl-1,5-dihydro-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-87-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1,5-dihydro-5-oxo-3-[(phenylmethoxy)methyl]-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-89-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[(1-(3,4-dimethylphenyl)-1,5-dihydro-3-[(methylthio)methyl]-5-oxo-4H-pyrazol-4-ylidene)hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-91-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(3-thienyl)-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-93-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-5-oxo-3-(3-thienyl)-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376593-95-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1,5-dihydro-3-[(methythio)methyl]-5-oxo-1-[4-(trifluoromethyl)phenyl]-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376593-98-5 CAPLUS
CN Methanesulfonamide, N-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-01-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,5-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376594-03-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-4'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-04-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3-chloro-4-methylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)




RN 376594-07-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-4'-hydroxy- (CA INDEX NAME)

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-12-6 CAPLUS
CN Phosphonic acid, P-[3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 376594-17-1 CAPLUS
CN [1,1'-Biphenyl]-3,4-dicarboxylic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)


L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 376594-38-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy[1,1'-biphenyl]-3-yl]methylene]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 376594-23-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2',4'-dihydroxy- (9CI) (CA INDEX NAME)




RN 376594-33-1 CAPLUS
CN [1,1'-Biphenyl]-3-sulfonic acid, 3'-[2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy- (CA INDEX NAME)

L4 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:296283 CAPLUS
DOCUMENT NUMBER: 137:311049
TITLE: New azo derivatives of gossypol. [Erratum to document cited in CA134:131685]
AUTHOR(S): Baran, N. I.; Ziyaev, Kh. L.; Ismailov, A. I.; Ziyamov, D.; Mangulova, Yu. S.
CORPORATE SOURCE: A. S. Sadykov Institute of Bioorganic Chemistry, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Russia
SOURCE: Chemistry of Natural Compounds (Translation of Khimiya Prirodnikh Soedinenii) (2001), Volume Date 2000, 36(5), 541-542
CODEN: CHNCAS; ISSN: 0009-3130
CONSULTANTS BUREAU
PUBLISHER: Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT: Table 1, omitted from the article, is given.

IT 321914-36-7P 321914-38-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (IR spectra and tautomerism of new azo derivs. of gossypol (Erratum))
RN 321914-36-7 CAPLUS
CN [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 4,4'-bis[2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl]azo]-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



L4 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 321914-38-9 CAPLUS
 CN [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 4,4'-bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)azo]-1,1',7,7'-tetrahydroxy-6,6'-dimethoxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A

L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:871702 CAPLUS
 DOCUMENT NUMBER: 134:131685
 TITLE: New azo derivatives of gossypol
 AUTHOR(S): Baran, N. I.; Ziyayev, Kh. L.; Ismailov, A. I.; Ziyamov, D.; Mangutova, Yu. S.
 CORPORATE SOURCE: A. S. Sadykov Institute of Bioorganic Chemistry, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Russia
 SOURCE: Chemistry of Natural Compounds (Translation of Khimiya Prirodnikh Soedinenii) (2000), 36(2), 185-188
 CODEN: CHNCAB; ISSN: 0009-3130
 PUBLISHER: Consultants Bureau
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:131685
 ABSTRACT: New azo deriva. of gossypol were described and their physicochem. properties were reported. The presence of hydroxyazo- and quinonhydrazo-tautomers was proposed.

IT 321914-36-7P 321914-38-9P
 RL: PRP (Properties): SPN (Synthetic preparation): PREP (Preparation) (IR spectra and tautomerism of new azo deriva. of gossypol)
 RN 321914-36-7 CAPLUS
 CN [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 4,4'-bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)azo]-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 321914-38-9 CAPLUS
 CN [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 4,4'-bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)azo]-1,1',7,7'-tetrahydroxy-6,6'-dimethoxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A

REFERENCE COUNT:


19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:35822 CAPLUS
 DOCUMENT NUMBER: 112:35822
 TITLE: Synthesis of some heterocycles of pharmaceutical interest
 AUTHOR(S): Metwally, Mohamed Abbas; El-Hussiny, M. S.; El-Ablak, F. Z.; Khalil, A. M.
 CORPORATE SOURCE: Fac. Sci., Univ. Mansoura, Egypt
 SOURCE: Pharmazie (1989), 44(4), 261-5
 CODEN: PHARAT; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 112:35822
 GRAPHIC IMAGE:



ABSTRACT: Condensation of cyclohexanonedicarboxylates 1 (R = Ph, 4-O₂NC₆H₄, 4-MeC₆H₄, 4-MeOC₆H₄) with 2-aminobenzimidazole, 3-amino-1,2,4-triazole, 5-aminotetrazole, 1-phenyl-3-aminopyrazole, 2-aminobenzothiazole, 2-amino-5-ethylthiadiazole, and substitution anilines was investigated. Some of the condensation products, e.g., dibenzoxazepine 11, showed bactericidal and fungicidal activities.

IT 124502-62-1P
 RL: SPN (Synthetic preparation): PREP (Preparation) (preparation, bactericidal, and fungicidal activity of)
 RN 124502-62-1 CAPLUS
 CN 3-Cyclohexene-1-carboxylic acid, 3-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)azo]-4,6-dihydroxy-2-(4-methoxyphenyl)-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:501821 CAPLUS
 DOCUMENT NUMBER: 109:101821
 TITLE: Electrophotographic photoreceptors containing an anthraquinone type azo compound as a charge-generating substance
 INVENTOR(S): Ehashi, Shigeyuki; Suda, Yasumasa; Sakamoto, Mare
 PATENT ASSIGNEE(S): Toyo Ink Mfg. Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7
 CODEN: JXXXXF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63005347	A	19880111	JP 1986-147114	19860625
PRIORITY APPLN. INFO.:			JP 1986-147114	19860625
OTHER SOURCE(S):		MARPAT 109:101821		
GRAPHIC IMAGE:				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


ABSTRACT:
 Electrophotog. photoreceptors have, on a conductive support, a photosensitive layer containing 21 azo compound of the formula I (R = H (R3 = (substituted) carbamoyl), III (R4 = H, (substituted) alkyl; R5 = (substituted) aryl), IV, V (R6 = (substituted) alkyl, aralkyl or aryl); R1, R2 = alkyl, alkoxy, halo, NO2, CN, OH; m, n = 0, 1). The photoreceptors exhibit good sensitivity and durability. Thus, an Al plate was coated with a composition containing VI and Vylon 200 (polyester resin) and overcoated with a composition containing a hydrazone charge-transporting substance, and Vylon 200 to give a photoreceptor which showed good sensitivity, durability, and environmental stability.

IT 115970-59-7
 RL: USES (Uses)
 (charge-generating agent, electrophotog. photoreceptor using)
 RN 115970-59-7 CAPLUS
 CN [2,2'-Bianthracene]-9,9',10,10'-tetrone, 7,7'-bis[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-1,1',4,4'-tetrahydroxy- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1986:131441 CAPLUS
 DOCUMENT NUMBER: 104:131441
 TITLE: Heterocyclic compounds containing basic and/or cationic groups and azo dyes prepared from them
 INVENTOR(S): Pedrazzi, Reinhard
 PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 71 pp.
 CODEN: GXXXXX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3503844	A1	19850814	DE 1985-3503844	19850205
FR 2559483	A1	19850816	FR 1985-1755	19850206
FR 2559483	B1	19861205		
GB 2153835	A	19850829	GB 1985-3089	19850207
GB 2153835	B	19871028		
CH 663814	A5	19871231	CH 1985-548	19850207
US 4686285	A	19870811	US 1985-699916	19850208
JP 60184563	A	19850920	JP 1985-23677	19850212
JP 06074383	B	19940921		
PRIORITY APPLN. INFO.:			DE 1984-3404778	A1 19840210
OTHER SOURCE(S):		MARPAT 104:131441		
GRAPHIC IMAGE:				



ABSTRACT:
 Comps. of general structure I (p = 1, Q = H) and their azo deriva. (I: p = 1, 2; Q = diazo or tetrazo component residue; metal-free or metalized) are prepared, where R = 0, NH, or S; R1 = Cl-4 alkyl, alkoxy, CO2H, etc.; R2 = OH, (un)substituted NH2, alkoxy, phenoxy, pyrazoline-containing group, or R3; R3 is through-N-bound organic radical containing 1-5 N atoms, one of more of which is basic or in ammonium form; Z = (un)substituted arylene; Z1 = bivalent bridging group; Z2 = (un)substituted NH or 1,4-piperazinediyl; a = 0 or 1; and x = 0 or 1 (a + x = 1 or 2). The azo deriva. (in salt form) are fast dyes for paper, cotton, and leather. Thus, reaction of cyanuric chloride with Et2N(CH2)3NH2 and then 1-(4-aminophenyl)-3-methyl-5-pyrazolone gave II (Q = H) (III). Coupling of III with diazotized 2-(4-aminophenyl)-6-methylbenzothiazole gave II [Q = 4-(6-methyl-2-benzothiazolyl)phenylazo], a yellow powder which, in the form of an acid salt, dyed paper in clear, yellow shades. Numerous other couplers and azo dyes were prepared.

L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PAGE 1-B

L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 100851-47-6DP, copper complex
 RL: INF (Industrial manufacture): PREP (Preparation)
 (preparation of, as dye for paper)
 RN 100851-47-6 CAPLUS
 CN 3H-Pyrazol-3-one, 4,4'-bis[(3,3'-dihydroxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[2-[4-[4,6-bis[[3-(diethylamino)propyl]amino]-1,3,5-triazin-2-yl]amino]phenyl]-2,4-dihydro-5-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1966:94027 CAPLUS
 DOCUMENT NUMBER: 64:94027
 ORIGINAL REFERENCE NO.: 64:17588-e
 TITLE: Metallizable, water-soluble dia- and trisazo dyes
 PATENT ASSIGNEE(S): Durand & Huguenin A.-G.
 SOURCE: 37 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 655489		19650510	BE	19641109
FR 1430162			FR	
PRIORITY APPLN. INFO.:			CH	19631108

ABSTRACT:


The title compds., prepared from tetrazotized diamines and suitable coupling components, dye natural and regenerated cellulose. Thus, 37.6 parts [4,3-H2N(HO3SO)C6H3]2 (I) was tetrazotized and coupled first with 51.9 parts 1,8,3,6-HO(ZSO2NH)C10H4 (SO3H)2 (II) [Z = 4,3-HO(HO3S)C6H3], then with 37.5 parts 5,2,7-HO(ZNH)C10H5 (SO5H) (III), and, when coupling was complete, the mixture was heated to 60% the dye precipitated with NaCl, filtered, and recrystd. from aqueous alc. and H2O. It dyed cotton navy blue when applied with Cr(OAc)3 and after-coppered. Similarly, other dyes were prepared [diamine tetrazotized, coupling component (2 mols.), and shade (Cr-Cu treatment) given]: I, III, blue violet; [3,4-H2N(HO3SO)C6H3]2 (IV), 2,4-(HO)2C6H3CO2H (V), violet-brown; [3,4-H2N(HO3SO)C6H3]2CMe2 (VI), 1-(4-hydroxy-3-carboxyphenyl)-3-methyl-5-pyrazolone, orange; [3,4-H2N(HO)C6H3]2SO2 (VII), 8,2,6-HO(ZSO2NH)C10H5SO3H, violet red; [4,3-H2N(MeO)C6H3]2 (VIII), 8,2,6-HO(ZSO2N(Me))C10H5SO3H, Cu complex formed and demetallized, navy blue; [4,2-H2N(HO3S)C6H3]2, 1-[2-(4-hydroxy-3-carboxyphenylsulfonyl)-5-sulfonylphenyl]-3-methyl-5-pyrazolone, coppered and then demetallized, brownish orange; 1,7,2-HO(C10H6NH)SO2Z, reddish blue (the remainder not subsequently coppered): [3,4,5-H2N(HO) (HO3S)C6H2]2SO2 (IX), III, navy blue; Cu complex of last, violet; Ni complex, violet; Cr complex, bluish gray; Co complex, reddish gray; [4-H2N(C6H4N)2]2, II, coppered, grayish blue; VIII, 5,1,7-HO [4,2,5-HO(Me) (HO2C)C6H2SO2NH]C10H5SO3H, coppered, blue; I, II, Cr complex, grayish blue; mixture of IX, V and IX, 1-(2-hydroxy-3-carboxy-5-sulfonylphenyl)-3-methyl-5-pyrazolone (Cr complex), red brown; (4-HO(C6H4)2, when nitrated, treated with ClSO3H, and reduced, gave IV; similarly, [4,3-HO(O2N)C6H3]2CMe2 gave VI; (4-HO(C6H4)2SO2 nitrated and reduced gave VII; and (4-HO(C6H4)2SO2, treated with ClSO3H, nitrated, and reduced, gave IX.

IT 5723-13-7P, Salicylic acid, 5,5'-(5,5'-dihydroxy-2,2'-disulfo-4,4'-biphenylene)bis[azo(3-methyl-5-oxo-2-pyrazoline-4,1-diyl)(4-sulfo-o-phenylene)sulfonyl]]di-
 RL: PREP (Preparation)

MANUFACTURE OF, AND USE IN AFTER-CHROME-AFTER-COPPER TEXTILE DYEING)

5723-13-7 CAPLUS
 CN Salicylic acid, 5,5'-(5,5'-dihydroxy-2,2'-disulfo-4,4'-biphenylene)bis[azo(3-methyl-5-oxo-2-pyrazoline-4,1-diyl)(4-sulfo-o-phenylene)sulfonyl]]di- (8C1) (CA INDEX NAME)

L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



PAGE 1-A



PAGE 1-B

L4 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1962:469768 CAPLUS
 DOCUMENT NUMBER: 57:69768
 ORIGINAL REFERENCE NO.: 57:13928b-1,13929a-c
 TITLE: Copper-containing azo dyes
 PATENT ASSIGNEE(S): Farbenfabriken Bayer, A.-G.
 SOURCE: 5 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 879235		19611011	GB 1960-8982	19600314
PRIORITY APPLN. INFO.:			DE	19590313

ABSTRACT:
 Cu complexes of dyes of the general formula 1,5,2,4,8-(HO)2(HORN:N) (HO3S)2C10H3, where R is the radical of a coupling component in which the O11 is ortho to the group, are dyes for animal and vegetable fibers. Thus, 2-amino-5,4-naphthosulfone-8-sulfonic acid (I) 30.1 was diazotized, coupled at 5' with a solution of 2,3,6-HO(HO3S)2C10H5 (II) 30.4 in H2O 350 and then treated with NaHO3 40 parts. The azo dye was precipitated with NaCl and the paste thus obtained dissolved in H2O 1700, treated with 20% NaOAc 140 vols, and a solution of CuSO4 25 in H2O 120 parts, then 3% H2O2 250 vols, was added at 20° within 90 min, until oxidative copperization was complete. The Cu complex was precipitated with NaCl, stirred in 500 parts H2O, treated with 50 parts by volume 40% NaOH, and stirred at 40-50° for 30 min. AcOH was added to pH 8. NaCl added, and the dye isolated as a dark powder, blue-violet in H2O, changing with NaOH to blue-green. Similarly, other dyes were prepared by oxidatively coppering and saponifying azo compds. (amine diazotized, coupling compound, and colors in H2O and NaOH given): I, 1,4-HO(HO3S)C10H6, (III), violet, blue; I, 2,5,7AcNH(HO) (HO3S)C10H5, violet blue; I, 1-(4-sulfonylphenyl)-3-methyl-5-pyrazolone (IV), red, red-violet; I, 1,4,6-HO(HO3S) (O2N)C10H5, blue-violet, blue-green. Other dyes were prepared: the coppered and saponified dye from diazotized I and 1,2,5,7-Cl (AcNH) (HO) (HO3S)C10H4 again diazotized and coupled with II, violet (H2O); the coppered and saponified dye from diazotized I and 2,5,4,8-AcNH(HO) (HO3S)2C10H4, converted with COC12 to the disubstituted urea, blue (H2O), blue-green (NaOH); tetrazotized diaminidine coupled first with the azo compound from diazotized I and III, and then with IV, the product copperized with demethylation gave a gray cotton dye; the Cu complex (oxidative coppering) of the dye prepared by coupling diazotized 2,5,4,8-H2N(PhSO3) (HO3S)2-C10H4 with III, violet (H2O).

IT 859451-36-8, 1,5-Naphthalenedisulfonic acid, 3-[[[3,3'-dihydroxy-4'-[3-methyl-5-oxo-1-(p-sulfonylphenyl)-2-pyrazolin-4-yl]azo]-4-biphenyl]azo]-4,8-dihydroxy-7-[(1-hydroxy-4-sulfo-2-naphthyl)azo]-
 (tricopper derivative)


859451-36-8 CAPLUS
 CN 1,5-Naphthalenedisulfonic acid, 3-[[[3,3'-dihydroxy-4'-[3-methyl-5-oxo-1-(p-sulfonylphenyl)-2-pyrazolin-4-yl]azo]-4-biphenyl]azo]-4,8-dihydroxy-7-[(1-hydroxy-4-sulfo-2-naphthyl)azo]- (7C1) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-B



L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1961:96333 CAPLUS
 DOCUMENT NUMBER: 55:96333
 ORIGINAL REFERENCE NO.: 55:181231, 18124a-e
 TITLE: Water-soluble dyes containing hydroxymethyl groups
 INVENTOR(S): Braun, Willy; Eiselo, Julius; Krehbiel, Gunther;
 Lange, Gunter; Mueller, Roland; Weissauer, Hermann
 PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik Akt.-Ges.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1079756		19600414	DE 1957-B44668	19570518

ABSTRACT:

The title compds., suitable for the dyeing of cotton, wool, silk, and leather, and having good affinity, were prepared by treating anthraquinone and azo dyes, metal-containing azo dyes, or their intermediates having reactive H atoms, with H₂CO or H₂CO-delivering compds. in weakly acid to basic medium. Thus, a solution of NaOH 4 and N-(3-hydroxyphenyl) urea (I) 15.2 in H₂O 80 treated with 30% H₂CO 40, the mixture kept 20 hrs. at room temperature, the clear yellow solution treated with Na₂CO₃ 15.9 in H₂O 1000, a diazo solution of aniline-4-sulfonamide (II) 17.2 parts added, the dye salted out with NaCl, filtered, and dried in vacuo at regular temperature yielded a product dyeing wool and cotton brownish yellow shades of good wet fastness. The same dye was obtained by stirring the monoazo dye at room temperature with 30% alkaline H₂CO. The diazo compound could be replaced by tetrazotized 4,4'-diaminobiphenyl. Similarly, the following compds. were treated with 30% H₂CO (color given): the monoazo dye prepared from II and 2-naphthol-6-sulfonamide: red-brown; 1-amino-4-(4-ureidophenylamino)anthraquinone-2-sulfonic acid, blue; dye prepared from tetrazotized benzidine, 1-amino-8-naphthol-3,6-disulfonic acid, diazotized N-(4-aminophenyl)urea, and I + H₂CO, black; diazotized 3-aminophenol coupled with 2-amino-6-naphthol-7-sulfonic acid, red-brown; diazotized II and the Na-salt of 2,4-bis(hydroxymethyl)phenol, yellow; diazotized aniline-4-sulfonic acid and 2-ureido-5-naphthol-7-sulfonic acid (III), red-violet; diazotized 2-amino-4-cyclohexyl-6-nitrophenol and 3-carbamoyl-1-(3-sulfamoylphenyl)-5-pyrazolone, violet; diazotized II and III, red; diazotized aniline-2-sulfonic acid and 2-(2-hydroxybenzylideneamino)-4,6-diamino-1,3,5-triazine (prepared from melamine, N-methylpyrrolidine and salicylaldehyde), reddish yellow; diazotized 2-(4-aminophenylsulfonamido)-4,6-diamino-1,3,5-triazine (IV) (prepared from melamine and 4-nitrobenzene-sulfonyl chloride and reduction) and 1-naphthol-3,6-disulfonic acid, orange-red; the dye prepared by coupling diazotized 2-aminonaphthalene-6,8-disulfonic acid and 2-(4-hydroxyanilino)-4,6-diamino-1,3,5-triazine, reddish yellow; phenol and diazotized 3,4-dichloroaniline-5-sulfonic acid, reddish yellow; the anthraquinone dye from 1-amino-4-bromoanthraquinone-2-sulfonic acid and IV, reddish blue; and 1,4-bis(2-sulfo-4-ureidoanilino)anthraquinone di-Na salt, green.

IT 113455-23-5, 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-5-oxo-1-m-sulfamoylphenyl- (reaction with HCHO, and dye therefrom)
 RN 113455-23-5 CAPLUS
 CN 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-5-oxo-1-m-sulfamoylphenyl- (6CI) (CA INDEX NAME)

L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1961:20140 CAPLUS
 DOCUMENT NUMBER: 55:20140
 ORIGINAL REFERENCE NO.: 55:3988e-i
 TITLE: Monoazo dyes containing sulfamoyl groups
 PATENT ASSIGNEE(S): Societe carbochimique S.A.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 585915		19600622	BE	

ABSTRACT:

Dyes containing 1 or 2 SO₂N(C₂H₄CN)₂alkyl groups (affording a strong affinity towards the fibers) and bearing a metal-complexing group (OH, COOH, NH₂) on each C ortho to the N-N bond, were prepared. The compds. containing the sulfamoyl group were prepared by reaction of a sulfonyl chloride, a monoalkyl amine, and acrylonitrile. For example, 4-[N-methyl-N-(2-cyanoethyl)sulfamoyl]-2-aminophenol (I) 25.5 g. was diazotized and added to a solution of 18.4 g. 1-phenyl-3-methyl-5-pyrazolone (II) in 300 g. H₂O containing 31 g. Na₂CO₃. After reaction, 5% NaCl was added, the precipitate was filtered, and dried, yielding a brownish red powder. This was dissolved in 120 g. HCOONH₂ containing 10 g. Cr formate; the mixture was heated at 120° for 1 hr., cooled to 95°, diluted with 500 g. hot H₂O (slowly) and cooled to room temperature before filtration. The moist precipitate was boiled in 250 g. H₂O containing 2 g. NaOH, then cooled; after addition of 5% NaCl, filtration, and drying, a dark red powder soluble in H₂O was obtained, which dyes wool (neutral or weakly acid medium) in orange tints. Similar tints were obtained with dyes prepared from N-Et or N-Bu derivs. The intermediate amines were prepared by condensation of 3-nitro-4-chlorobenzenesulfonyl chloride with MeNH₂, EtNH₂, or BuNH₂, hydrolysis of Cl, condensation with acrylonitrile, and reduction. 5-[N-Methyl-N-(2-cyanoethyl)sulfamoyl]-2-aminophenol, m. 115°, obtained by condensation of 2-oxo-6-benzoxazolin-sulfonyl chloride and methyl-cyanoethylamine, followed by hydrolysis of the oxazolone ring, was condensed with II; the corresponding Cr complex dyes wool in red tints. The condensation product of diazotized I and 2-naphthol, treated with Co sulfate in aqueous medium, yielded a dark violet dye. A mixture of the latter monoazo dye, 41.1 g., and the reaction product of diazotized 5-nitro-2-aminophenol with l-acetamido-7-naphthol (III) 36.6 g., was refluxed for 10 hrs. in 4 l. H₂O containing 27 g. NaOH and Na Cr salicylate solution; after addition of 15% NaCl, filtration and drying, a black dye was obtained.

IT 102549-86-0P, 4-Biphenylsulfonamide, 4'-hydroxy-3'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-
 RL: PREP (Preparation)
 (preparation of)
 RN 102549-86-0 CAPLUS
 CN 4-Biphenylsulfonamide, 4'-hydroxy-3'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)- (6CI) (CA INDEX NAME)



L4 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1961:20139 CAPLUS
 DOCUMENT NUMBER: 55:20139
 ORIGINAL REFERENCE NO.: 55:3988a-e
 TITLE: Monazo dyes and their metal complex compounds
 INVENTOR(S): Dorlars, Alfons
 PATENT ASSIGNEE(S): Farbenfabriken Bayer Akt.-Ges.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1046220		19581211	DE 1956-F20107	19560421

ABSTRACT:

The dyes were obtained by coupling diazotized 3-amino-4-hydroxybiphenyl derivs. with coupling components selected from the naphthol, pyrazolone, or acetoacetic arylide series which are free of SO₃H or CO₂H groups. The diazo components were obtained by the following 4 steps: 1) reaction of 4-nitrobiphenyl-4'-sulfonfyl chloride with NaOH or primary or secondary amines; 2) reduction of the nitro groups; 3) conversion of these amino groups into OH groups by diazotization and boiling in the presence of dilute H₂SO₄; and 4) introduction of an amino group in the 3-position either by nitration and subsequent reduction or by coupling with suitable diazonium compds. and subsequent reductive decomposition. Thus, the following new compds. were prepared as intermediates in the preparation of the diazo compds.: nitrobiphenylsulfonamides (m.p. given): amide (yellowish leaves, 227-8°) methylamide (yellowish crystals, 169-70°), 2-hydroxy-ethylamide (weakly orange crystals, 158-60°); aminobiphenylsulfonamides: amide (colorless crystals, 269-70°), methylamide (colorless crystals, 179-80°), 2-hydroxyethylamide (colorless crystals, 198-9°); hydroxybiphenylsulfonamides: amide (colorless prisms, 267-8°), methylamide (colorless crystals, 170°), 2-hydroxyethylamide (colorless crystals, 222-3°); 3-amino-4-hydroxybiphenyl-4'-sulfonamides: amide (I) (nearly colorless crystals, 260-1°) methylamide (II) (light grey crystals, 182-3°) 2-hydroxyethylamide (III) (nearly colorless crystals, 165-6°). The metal-free dyes dye wool by the 1-bath chromeing method to give dyeings of excellent light- and milling-fastness. They may further be converted into their Co or Cr complex compds. Both the metalized and metal-free compds. dye wool, silk, polyamides, and polyurethans from weakly acid or neutral baths. Thus, new monazo dyes were obtained from the following components (appearance, shade on wool, and metal, if used, given): III and 2-naphthol (black powder, Bordeaux, Co); I and 4-hydroxynaphthol(2',1',4,5)oxathiole S-oxide (black powder, greenish dark blue); II and 1-acetamido-7-naphthol (dark blue powder, bluish grey, Cr); I and 1-phenyl-3-methyl-5-pyrazolone (dark powder, orange brown, Co); I and acetoacetic anilide (brown powder, brownish yellow, Co); II and 6-acetamido-2-naphthol (dark powder, greenish blue-grey, Cr).

IT 102549-86-OP, 4-Biphenylsulfonamide, 4'-hydroxy-3'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-
 RL: PREP (Preparation)
 (preparation of)
 RN 102549-86-0 CAPLUS
 CN 4-Biphenylsulfonamide, 4'-hydroxy-3'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)- (6C1) (CA INDEX NAME)

L4 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1958:23286 CAPLUS
 DOCUMENT NUMBER: 52:23286
 ORIGINAL REFERENCE NO.: 52:4191h-i, 4192a-c
 TITLE: Azo dyes
 INVENTOR(S): Hanhart, Walter
 PATENT ASSIGNEE(S): C I B A Ltd.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2809963		19571015	US 1955-540623	19551014

GRAPHIC IMAGE:

For diagram(s), see printed CA issue.


ABSTRACT:

New direct dyes with blue shades particularly fast to light and washing, are described. They have the general formula I, where R is 4,4'-biphenyl group substituted in 3,3'-positions by metal-complexing groups, such as OH, R' is a coupling component joined to the azo group by a ketomethylene group, R'' is a sulfo-substituted phenylene or biphenyl group, and R''' is the radical of 8-quinolinol. Thus, 10.8 parts 3,3'-dihydroxy-4,4'-diaminobiphenyl are tetrazotized, the suspension treated with 15 parts NaCl per 100 parts by volume, and filtered. The tetrazo compound is added to a cold solution of 20.5 parts 2-(4-amino-3-sulfonylamino)-5-hydroxy-7-naphthalenesulfonic acid in water 100 and stirring continued to complete coupling. The product is filtered and washed with dilute NaCl solution. The cake is suspended in cold water, treated with a solution of 1-phenyl-3-methyl-5-pyrazolone (II) 9.6 in water 50, 30% NaOH 7.3, and Na₂CO₃ 10, and then with pyridine 50 parts. After stirring and raising the temperature to 30°, the dye is filtered, washed with dilute salt solution, suspended in cold water 1000, treated with 2N NaOH 50 (by volume) and 2N NaNO₂ 25 (by volume), and the whole poured into 30% HCl 35 parts in a small amount of water. After stirring for a few hrs. at 10°, there is added 8-quinolinol 8, dissolved in water 50 and 30% HCl 7, and then an aqueous solution of Na₂CO₃ 30 parts. The whole is stirred to room temperature and filtered to give the dye, a dark powder, soluble in H₂SO₄ with blue color, blue-violet in water, dyeing cotton, after coppering, navy-blue shades fast to washing and light. Similar properties are obtained by replacing II with 1-(3-sulfonylphenyl)-3-methyl-5-pyrazolone or 1-(4-sulfonylphenyl)-3-methyl-5-pyrazolone.


IT 103389-78-2P, 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-4-biphenylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]-108670-01-5P, Salicylic acid, 5-[4-[3,3'-dihydroxy-4'-(1-hydroxy-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]-3-sulfo-2-naphthylazo)-4-biphenylazo]-3-methyl-5-oxo-2-pyrazolin-1-yl]-116151-20-3P, 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-4-biphenylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]-124132-51-OP, 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-4-biphenylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]-853647-00-4P, 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-4-biphenylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]-
 RL: PREP (Preparation)
 (preparation of)
 RN 103389-78-2 CAPLUS
 CN 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-phenyl-2-pyrazolin-4-ylazo)-4-biphenylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]- (6C1) (CA INDEX NAME)

L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



Me




PAGE 2-A


RN 108670-01-5 CAPLUS
 CN Salicylic acid, 5-[4-[3,3'-dihydroxy-4'-(1-hydroxy-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]-3-sulfo-2-naphthylazo)-4-biphenylazo]-3-methyl-5-oxo-2-pyrazolin-1-yl]- (6C1) (CA INDEX NAME)

L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




PAGE 2-B

OH

RN 116151-20-3 CAPLUS
 CN 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-m-sulfonylphenyl)-2-pyrazolin-4-ylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]- (6C1) (CA INDEX NAME)

L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




PAGE 2-B




RN 124132-51-0 CAPLUS
 CN 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-m-sulfonylphenyl)-2-pyrazolin-4-ylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]- (6C1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B


SO3H

RN 853647-00-4 CAPLUS
 CN 1-Naphthol-3-sulfonic acid, 2-[3,3'-dihydroxy-4'-(3-methyl-5-oxo-1-m-sulfonylphenyl)-2-pyrazolin-4-ylazo]-6-[4-(8-hydroxy-5-quinolylazo)-3-sulfonylino]- (6C1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-B

SO3H


L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1954:51196 CAPLUS
 DOCUMENT NUMBER: 48:51196
 ORIGINAL REFERENCE NO.: 48:9072g-h
 TITLE: Pyrazolone monoozo dyes
 PATENT ASSIGNEE(S): J. R. Geigy, A.-G.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 697517		19530923	GB 1951-28983	19511211

ABSTRACT:
 See U.S. 2,659,720 (C. A. 48, 4846e).

IT 873397-51-4P, 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-5-oxo-1-m-sulfamoylphenyl-
 873397-52-5P, 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-1-[m-(methylsulfamoyl)phenyl]-5-oxo-
 RL: PREP (Preparation)
 (preparation of)

RN 873397-51-4 CAPLUS
 CN 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-5-oxo-1-m-sulfamoylphenyl- (5C1) (CA INDEX NAME)



RN 873397-52-5 CAPLUS
 CN 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-1-[m-(methylsulfamoyl)phenyl]-5-oxo- (5C1) (CA INDEX NAME)


L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1954:51195 CAPLUS
 DOCUMENT NUMBER: 48:51195
 ORIGINAL REFERENCE NO.: 48:9072g
 TITLE: Copper monoozo dyes
 PATENT ASSIGNEE(S): Farbenfabriken Bayer
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 704553		19540224	GB 1951-11688	19510518

ABSTRACT:
 See U.S. 2,669,561 (C. A. 48, 7309i).


IT 873397-51-4P, 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-5-oxo-1-m-sulfamoylphenyl-
 873397-52-5P, 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-1-[m-(methylsulfamoyl)phenyl]-5-oxo-
 RL: PREP (Preparation)
 (preparation of)

RN 873397-51-4 CAPLUS
 CN 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-5-oxo-1-m-sulfamoylphenyl- (5C1) (CA INDEX NAME)




RN 873397-52-5 CAPLUS
 CN 2-Pyrazoline-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-1-[m-(methylsulfamoyl)phenyl]-5-oxo- (5C1) (CA INDEX NAME)

L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1954:26824 CAPLUS
 DOCUMENT NUMBER: 48:26824
 ORIGINAL REFERENCE NO.: 48:4846e-1
 TITLE: Pyrazolone monoazo dyes
 INVENTOR(S): Kuster, Werner
 PATENT ASSIGNEE(S): J. R. Geigy A.-G.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2659720		19531117	US 1951-259695	19511203

ABSTRACT:
 Chromable monoazo dyes suitable for dyeing keratin fibers according to the single bath chroming method are prepared by coupling diazotized 6-nitro-4-alkyl-2-aminophenols with 1-(3-sulfamoylphenyl)-5-pyrazolone-3-carboxamides. These dyes are violet-brown powders, bluish red in H₂O, orange in conductivity H₂SO₄, and produce full and fast bluish red wool dyeings. Thus 6-nitro-2-amino-4-tert-amylphenol (I) 22.4 and NaOH 4.1 are dissolved in H₂O 200 parts, a solution of NaNO₂ 6.9 in H₂O 35 parts is added, and the whole mixture added dropwise to concentrated HCl 25 parts by volume and H₂O 100 parts at a temperature below 3°. The greenish yellow diazo suspension is neutralized to Congo red with NaHCO₃ and a solution of 1-(3-sulfamoylphenyl)-5-pyrazolone-3-carboxamide 28.5 and NaOH 8 in H₂O 100 parts is added at 0-3°. The reaction mixture is made alkaline to phenolphthalein by the addition of 25% NH₄OH 10 parts and the temperature of the reaction mixture allowed to rise to 20°. Coupling is completed after 20 hrs. and the dark violet solid is filtered and dried. A similar dye is obtained by treating diazotized I with ethyl 1-(3-sulfamoylphenyl)-5-pyrazolone-3-carboxylate. This coupling product is heated at room temperature in a closed vessel for 3 days with 20-30% aqueous MeNH₂ to give a blue-red wool dye. Similar dyes are also prepared by coupling diazotized 6-nitro-2-amino-4-cyclohexylphenol with N-methyl-1-(3-methylsulfamoylphenyl)-5-pyrazolone-3-carboxamide; diazotized 6-nitro-2-amino-4-tert-butylphenol with 1-(2-chloro-5-sulfamoylphenyl)-5-pyrazolone-3-carboxamide; diazotized I with 1-(4-chloro-5-sulfamoylphenyl)-5-pyrazolone-3-carboxamide; and diazotized I with ethyl 1-(4-chloro-5-sulfamoylphenyl)-5-pyrazolone-3-carboxylate followed by treatment with 25% NH₃. The dye products when mixed with 10% of their weight of Na₂CO₃ and 2% of a dispersing agent dye wool from an acid bath in a brown-orange shade which on afterchroming changes to blue-red.


IT 873397-51-4P. 2-Pyrazolone-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-5-oxo-1-m-sulfamoylphenyl-
 873397-52-5P. 2-Pyrazolone-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-1-[m-(methylsulfamoyl)phenyl]-5-oxo-
 RL: PREP (Preparation)
 (preparation of)
 RN 873397-51-4 CAPLUS
 CN 2-Pyrazolone-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-5-oxo-1-m-sulfamoylphenyl- (SCI) (CA INDEX NAME)

L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1953:64125 CAPLUS
 DOCUMENT NUMBER: 47:64125
 ORIGINAL REFERENCE NO.: 47:10859h-1, 10860a
 TITLE: Chromable azo dyes
 INVENTOR(S): J. R. Geigy A.-G.
 SOURCE: Addn. to Swiss 261,126 (C.A. 44, 9682b)
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 281646		19520616	CH	

ABSTRACT:
 2-Amino-1-hydroxy-4-Ph Me sulfone (I) 18.7 is diazotized, neutralized with Na₂CO₃, and coupled at 0-5° with the 7-hydroxy-1-naphthalenecarboxylic acid ester with Me glycolate 27.4, waterfree Na₂CO₃ 15, and 30% NaOH 200 parts. The Cr complex is prepared by refluxing the Na salt 48.1 of the dye in H₂O 650 with the ammonium salicylate-Cr complex 11 parts. It is a blue-black powder which dyes wool from neutral or weakly organic acid baths in gray, very light, and washfast shades. In Swiss 281,647, diazotized 5-nitro-2-amino-1-hydroxy-4-Ph Me sulfone (II) is treated with 1-phenyl-3-methyl-5-pyrazolone. A scarlet Cr dye is obtained.


IT 874490-50-3P. 2-Pyrazolone-3-carboxylic acid, 1-(m-chlorophenyl)-4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-5-oxo-
 RL: PREP (Preparation)
 (preparation of)
 RN 874490-50-3 CAPLUS
 CN 2-Pyrazolone-3-carboxylic acid, 1-(m-chlorophenyl)-4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-5-oxo- (SCI) (CA INDEX NAME)



L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 873397-52-5 CAPLUS
 CN 2-Pyrazolone-3-carboxamide, 4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-N-methyl-1-[m-(methylsulfamoyl)phenyl]-5-oxo- (SCI) (CA INDEX NAME)




L4 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1953:53216 CAPLUS
 DOCUMENT NUMBER: 47:53216
 ORIGINAL REFERENCE NO.: 47:9020d-f
 TITLE: Chromable monoazo dyes
 INVENTOR(S): Kuster, Werner
 PATENT ASSIGNEE(S): J. R. Geigy A.-G.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2633463		19530331	US 1951-227120	19510518

ABSTRACT:
 Fast red dyeings on wool by afterchroming or by the single bath chrome process are given by the products obtainable by coupling a diazotized 6-nitro-4-alkyl- (or cycloalkyl)-2-aminophenol (where the aliphatic or alicyclic radical consists of 5-8 C atoms) with 1-(3-chlorophenyl)-5-pyrazolone-3-carboxylic acid (I), 1-(3,4-dichlorophenyl)-5-pyrazolone-3-carboxylic acid (II), or 1-(3,6-dichlorophenyl)-5-pyrazolone-3-carboxylic acid (III). Thus, 6-nitro-4-cyclohexyl-2-aminophenol (IV) 23.6 parts is diazotized and coupled with I 24. The chromed color of the product on wool is bluish red. Similar dyes are obtained when diazotized 6-nitro-4-tert-amyl-2-aminophenol (V) or 6-nitro-4-octyl-2-aminophenol (VI) is coupled with I; when diazotized V or IV is coupled with II, or when diazotized V or VI is coupled with III.

IT 874490-50-3P. 2-Pyrazolone-3-carboxylic acid, 1-(m-chlorophenyl)-4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-5-oxo-
 RL: PREP (Preparation)
 (preparation of)

RN 874490-50-3 CAPLUS
 CN 2-Pyrazolone-3-carboxylic acid, 1-(m-chlorophenyl)-4-(5-cyclohexyl-2-hydroxy-3-nitrophenylazo)-5-oxo- (SCI) (CA INDEX NAME)



L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1950:31594 CAPLUS
 DOCUMENT NUMBER: 44:31594
 ORIGINAL REFERENCE NO.: 44:6146g-1, 6147a-g
 TITLE: Polyoazo dyes
 PATENT ASSIGNEE(S): J. R. Geigy A.-G.
 SOURCE: Addn. to Swiss 248, 806
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 254147		19490117	CH	

GRAPHIC IMAGE: For diagram(s), see printed CA Issue.


ABSTRACT:

Tetrazazo dyes for cellulose fibers that are aftertreated on the fiber with CuSO₄ and have good general fastness properties are described. For example, 4,4'-dihydroxy-3,3'-diaminodiphenyl sulfone 28 is tetrazotized with NaNO₂ 13 in HCl solution. The tetrazo solution is neutralized with Na₂CO₃ to Congo neutral and mixed with a Na₂CO₃-alkaline solution of 139.8 parts of the mono-coupled monazo dye (I) from the diazo compound of 1-amino-6-nitro-2-hydroxy-4-naphthalenesulfonic acid and the sym. urea of 1-(4-aminophenyl)-3-methyl-5-pyrazolone. The dye [3,4-(HO)C₆H₃]2SO₂ gives a brown shade on cotton, changing to orange-red on aftertreatment with CuSO₄. In Swiss 254, 148, a red dye of the formula p-(p-RC₆H₄NHCO)C₆H₄R, is obtained on aftertreated cotton if the tetrazo is made from 22.7 parts of 1-(4-aminobenzamido)-4-aminobenzene and is coupled with I 139.8 in NaHCO₃ medium. In Swiss 254, 149, Jan. 3, 1949, the tetrazo dye [3,4-(HO)C₆H₃]2, is derived from 21.6 parts of 4,4'-diamino-3,3'-dihydroxybiphenyl and is coupled in Na₂CO₃-alkaline medium with 139.8 parts of I. The after-treated dyeing is red. In Swiss 254, 150, I 139.8 is coupled in NaHCO₃-alkaline medium with the tetrazo of 4,4'-diamino-2,2'-stilbene disulfonic acid 37 to give a dye [2,4-(HO₂)C₆H₃CH]₂. The CuSO₄ aftertreatment changes the shade from reddish brown to red. In Swiss 254, 151, Dec. 16, 1948, a triazo dye is described of the formula 2,5-(HO)(p-RC₆H₄CO₂NH₂)C₆H₃CO₂NH. Benzidine 18.4 is tetrazotized and coupled, first with salicylic acid 13.8 in Na₂CO₃-alkaline medium and then with 40.4 parts of the urea of 1-(4-aminophenyl)-3-methyl-5-pyrazolone. The diazotized 1-amino-6-nitro-2-hydroxy-4-naphthalenesulfonic acid 28.4 is then coupled in Na₂CO₃-alkaline medium with the above diazo dye. CuSO₄ aftertreatment on cotton changes the shade from reddish brown to an orange. In Swiss 254, 152, 4,4'-diaminobiphenyl-3'-sulfonic acid 26.4 is tetrazotized and coupled in NaHCO₃ solution with I 139.8 to give 2,5-R(p-RC₆H₄)C₆H₃SO₃H. The reddish brown shade on cotton changes to a red on aftertreatment with CuSO₄. In Swiss 254, 153, the tetrazo dye (p-RC₆H₄NH)2CO is derived from 24.2 parts of 4,4'-diaminodiphenylurea. The coupling with I 139.8 is finished under Brilliant Yellow-alkaline conditions. The dyeing is brownish red on cotton, changing to a red on CuSO₄ aftertreatment. In Swiss 254, 154, the tetrazo dye, [3,4-(HO₂C)C₆H₃]2 is derived from 27.2 parts of 4,4'-diaminobiphenyl-3,3'-dicarboxylic acid and is coupled in Na₂CO₃-alkaline medium with I 139.8. The reddish brown shade on cotton is changed to a red on CuSO₄ aftertreatment. In Swiss 254, 155, Jan. 3, 1949, the combination is benzidine 18.4 tetrazotized and coupled in NaHCO₃ solution with 143 parts of the sym. thiourea analog of I to give (p-R'C₆H₄)2. A brownish red shade on cotton is changed to red with the CuSO₄ aftertreatment. Alternate procedure of preparing the above nine dyes are indicated.


IT 866912-54-1P, m,m'-Biphenol, 4,4'-bis[1-[p-[3-[p-[4-(2-hydroxy-6-nitro-4-sulfo-1-naphthylazo)-3-methyl-5-oxo-2-pyrazolin-1-yl]phenyl]ureido]phenyl]-3-methyl-5-oxo-2-pyrazolin-4-ylazo]-
 RL: PREP (Preparation)

L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (prepn. of)
 RN 866912-54-1 CAPLUS
 CN m,m'-Biphenol, 4,4'-bis[1-[p-[3-[p-[4-(2-hydroxy-6-nitro-4-sulfo-1-naphthylazo)-3-methyl-5-oxo-2-pyrazolin-1-yl]phenyl]ureido]phenyl]-3-methyl-5-oxo-2-pyrazolin-4-ylazo]- (5C1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-B



10/516,988

Page 55

=> => d que 17 stat

L6 52 SEA FILE=CAPLUS ABB=ON PLU=ON ("HEERDING DIRK"/AU OR
 "HEERDING DIRK A"/AU OR "HEERDING DIRK ANDRIES"/AU)
L7 3 SEA FILE=CAPLUS ABB=ON PLU=ON L6 AND THROMBOPOIETIN

=> d 1-3 ibib iabs

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:87895 CAPLUS
 DOCUMENT NUMBER: 144:246534
 TITLE: New benzimidazoles as thrombopoietin receptor agonists
 AUTHOR(S): Safonov, Igor G.; Heerding, Dirk A.; Keenan, Richard M.; Price, Alan T.; Erickson-Miller, Connie L.; Hopson, Christopher B.; Levin, Jenna L.; Lord, Kenneth A.; Tapley, Peter M.
 CORPORATE SOURCE: Medicinal Chemistry and Oncology Research Departments, Microbial, Musculoskeletal and Proliferative Diseases, GlaxoSmithKline Pharmaceuticals, Collegeville, PA, 19426, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1212-1216
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:246534
 ABSTRACT: A novel benzimidazole series of small-mol. thrombopoietin receptor agonists has been discovered. Herein, we discuss the preliminary exploration of structure-activity relationships within this chemotype.
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:531312 CAPLUS
 DOCUMENT NUMBER: 141:94293
 TITLE: Preparation and formulation of thrombopoietin mimetics
 INVENTOR(S): Heerding, Dirk A.; Price, Alan T.; Safonov, Igor
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054515	A2	20040701	WO 2003-US39633	20031212
WO 2004054515	A3	20041118		
W: AE, AG, AL, AU, BA, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GE, GR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003297925	A1	20040709	AU 2003-297925	20031212
EP 1581527	A2	20051005	EP 2003-796996	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514951	T	20060518	JP 2004-560836	20031212
US 2006084682	A1	20060420	US 2005-538252	20050609
PRIORITY APPL. INFO.:			US 2002-433482P	P 20021213
			WO 2003-US39633	W 20031212

OTHER SOURCE(S): MARPAT 141:94293
 ABSTRACT: Invented are non-peptide thrombopoietin (TPO) mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected benzimidazole derivative. For example, a TPO receptor agonist, (E)-3-[2-[6-(4-tert-butylphenyl)pyridin-2-yl]-1H-benzimidazol-5-yl]-2-methylacrylic acid (I), was prepared and formulated into tablets containing 120 mg. calcium sulfate dihydrate 30 mg. sucrose 4 mg. starch 2 mg. talc 1 mg. and stearic acid 0.5 mg.

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:991360 CAPLUS
 DOCUMENT NUMBER: 140:42170
 TITLE: Preparation of arylazopyrazoles as thrombopoietin mimetics
 INVENTOR(S): Heerding, Dirk A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103686	A1	20031218	WO 2003-US17837	20030606
W: AE, AG, AL, AU, BA, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GE, GR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248630	A1	20031222	AU 2003-248630	20030606
EP 1556059	A1	20050727	EP 2003-757372	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501164	T	20060112	JP 2004-510805	20030606
US 2005234020	A1	20051020	US 2004-516988	20041206
PRIORITY APPL. INFO.:			US 2002-386694P	P 20020608
			US 2003-463241P	P 20030416
			WO 2003-US17837	W 20030606

OTHER SOURCE(S): MARPAT 140:42170
 GRAPHIC IMAGE:



ABSTRACT: Title compds. 1 [R-R3 = H, (un)substituted alkyl, alkenyl, aryl, OH, SH, S(O)H, SO2H, NH2, CONH2, SO2NH2, CO2H, CHO, NO2, CN, halogen, cycloalkyl, P(O)(OH)2, SO3H, P(O)(OH)(OH), heterocyclidenemethyl; m = 0-6; R4 = (un)substituted alkyl, aryl, OH, halogen; R5 = (un)substituted cycloalkyl] were prepared for use as ***thrombopoietin*** mimetics in treating thrombocytopenia (no data). Thus, cyclohexylhydrazine hydrochloride was treated with MeCOCH2CO2Me to give 2-cyclohexyl-5-methyl-2,4-dihydropyrazol-3-one which was treated with 3,2-H2N(HO)C6H3C6H4CO2H-2 to give 1 [R = 2-Ho2CC6H4, R1-R3 = H, R4 = Me, R5 = cyclohexyl, m = 0].

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/516,988

Page 57

=> log h

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

190.50

363.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

TOTAL
SESSION

CA SUBSCRIBER PRICE

-26.52

-26.52

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:19:52 ON 13 NOV 2007